Detalles de la búsqueda
1.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 29-45, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101433
2.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 46-61, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101431
3.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
4.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564933
5.
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Cancer Immunol Immunother
; 72(6): 1365-1379, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36633661
6.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248424
7.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
8.
Expert design thinking workshops to analyze users' perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study.
Support Care Cancer
; 31(9): 548, 2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37656215
9.
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.
Oncologist
; 27(4): e328-e339, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35380724
10.
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors.
Neuroendocrinology
; 112(12): 1155-1167, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35537416
11.
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Neuroendocrinology
; 112(1): 88-100, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-33508849
12.
High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?
Curr Treat Options Oncol
; 23(7): 1001-1013, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35501552
13.
177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1752-1763, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34793718
14.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10236): 1547-1557, 2020 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416780
15.
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Oncologist
; 26(11): 941-949, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34190375
16.
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
Br J Clin Pharmacol
; 87(7): 2867-2878, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33300203
17.
Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
Int J Mol Sci
; 22(2)2021 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33451055
18.
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Oncologist
; 25(9): 745-e1265, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32045050
19.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28076709
20.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32123969